Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis

Bevacizumab (BEV) is a key anti-angiogenic agent used in the treatment for recurrent glioblastoma multiforme (GBM). The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: YAMAGUCHI, Shigeru, MOTEGI, Hiroaki, ISHI, Yukitomo, OKAMOTO, Michinari, SAWAYA, Ryosuke, KOBAYASHI, Hiroyuki, TERASAKA, Shunsuke, HOUKIN, Kiyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048115/
https://www.ncbi.nlm.nih.gov/pubmed/33658457
http://dx.doi.org/10.2176/nmc.oa.2020-0308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048115/
https://www.ncbi.nlm.nih.gov/pubmed/33658457
http://dx.doi.org/10.2176/nmc.oa.2020-0308

Ejemplares similares